GlassScriptPhysician profile
Milli Gupta
NPI 1477831097
$4,371.79
in general payments reported to CMS, 2019-2025
34 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,441 · 2020: $281 · 2021: $111 · 2022: $248 · 2023: $538 · 2024: $591 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,779 · Gift: $350 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,779.34 |
| Gift | $350.00 |
| Education | $161.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $448.29 | 2019-2024 | |
| Medtronic, INC. | $406.42 | 2023-2025 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Celltrion, INC. | $350.00 | 2025 | Stoboclo |
| Insulet Corporation | $240.58 | 2022-2023 | Omnipod |
| Abbott Laboratories | $233.74 | 2019-2023 | Freestyle Libre 3 |
| Lilly USA, LLC | $219.88 | 2019-2025 | Jardiance |
| Beta Bionics, INC. | $209.16 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Astrazeneca Pharmaceuticals LP | $205.84 | 2019-2020 | |
| Mannkind Corporation | $199.19 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $193.71 | 2019-2021 | |
| Horizon Therapeutics Plc | $143.60 | 2019-2023 | Tepezza |
| Madrigal Pharmaceuticals | $140.35 | 2025 | Rezdiffra |
| Shire North American Group INC | $139.52 | 2019 | |
| Sequel Med Tech, LLC | $134.32 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $127.24 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $125.00 | 2024 | Watchman Access System |
| Cequr Corporation | $117.20 | 2023 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $95.25 | 2025 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $94.45 | 2019 | |
| Abbvie INC. | $80.32 | 2019-2025 | |
| Dexcom, INC. | $73.10 | 2024 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $63.63 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $60.08 | 2019-2020 | |
| Ibsa Pharma INC. | $45.62 | 2019-2020 | |
| Amarin Pharma, INC. | $35.70 | 2019 | |
| Corcept Therapeutics | $32.11 | 2019-2020 | |
| Tandem Diabetes Care, INC. | $31.40 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $21.73 | 2025 | |
| Becton, Dickinson and Company | $21.05 | 2019 | |
| Ucb, INC. | $19.78 | 2019 | |
| Medtronic Minimed, INC. | $18.50 | 2019 | |
| Gilead Sciences, INC. | $17.30 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.67 | 2019 | |
| Companion Medical, INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milli Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.